Logo image of UBX

UNITY BIOTECHNOLOGY INC (UBX) Stock Price, Quote, News and Overview

NASDAQ:UBX - Nasdaq - US91381U2006 - Common Stock - Currency: USD

1.12  +0.02 (+1.82%)

UBX Quote, Performance and Key Statistics

UNITY BIOTECHNOLOGY INC

NASDAQ:UBX (5/2/2025, 4:30:02 PM)

1.12

+0.02 (+1.82%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High3.1
52 Week Low0.85
Market Cap18.89M
Shares16.87M
Float16.50M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-13 2025-05-13/amc
IPO05-03 2018-05-03


UBX short term performance overview.The bars show the price performance of UBX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40

UBX long term performance overview.The bars show the price performance of UBX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of UBX is 1.12 USD. In the past month the price increased by 13.13%. In the past year, price decreased by -30.43%.

UNITY BIOTECHNOLOGY INC / UBX Daily stock chart

UBX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.33 351.09B
AMGN AMGEN INC 13.55 151.20B
GILD GILEAD SCIENCES INC 13.4 129.08B
VRTX VERTEX PHARMACEUTICALS INC 1728.1 128.84B
REGN REGENERON PHARMACEUTICALS 13.67 65.39B
ARGX ARGENX SE - ADR 341.93 39.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.74B
ONC BEIGENE LTD-ADR N/A 27.56B
BNTX BIONTECH SE-ADR N/A 25.23B
NTRA NATERA INC N/A 21.18B
SMMT SUMMIT THERAPEUTICS INC N/A 20.72B
BIIB BIOGEN INC 7.81 18.10B

About UBX

Company Profile

UBX logo image Unity Biotechnology, Inc. operates as a biotechnology company. The company is headquartered in South San Francisco, California and currently employs 16 full-time employees. The company went IPO on 2018-05-03. The firm is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. The company is targeting specific biological mechanisms implicated in diseases of aging. Its core therapeutic approach targets cellular senescence, and it is advancing senolytic programs primarily in ophthalmologic disorders. The company has other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease. UBX1325 is its advanced drug candidate for age-related diseases of the eye, including diabetic macular edema. UBX1325 is a potent small molecule inhibitor of BCL-xL. UBX2089, an α-Klotho hormone drug candidate, is being researched for multiple neurology indications.

Company Info

UNITY BIOTECHNOLOGY INC

285 East Grand Avenue

South San Francisco CALIFORNIA US

Employees: 19

Company Website: https://unitybiotechnology.com/

Investor Relations: https://ir.unitybiotechnology.com/

Phone: 16504161192

UNITY BIOTECHNOLOGY INC / UBX FAQ

What is the stock price of UNITY BIOTECHNOLOGY INC today?

The current stock price of UBX is 1.12 USD. The price increased by 1.82% in the last trading session.


What is the ticker symbol for UNITY BIOTECHNOLOGY INC stock?

The exchange symbol of UNITY BIOTECHNOLOGY INC is UBX and it is listed on the Nasdaq exchange.


On which exchange is UBX stock listed?

UBX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for UNITY BIOTECHNOLOGY INC stock?

8 analysts have analysed UBX and the average price target is 5.1 USD. This implies a price increase of 355.36% is expected in the next year compared to the current price of 1.12. Check the UNITY BIOTECHNOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is UNITY BIOTECHNOLOGY INC worth?

UNITY BIOTECHNOLOGY INC (UBX) has a market capitalization of 18.89M USD. This makes UBX a Nano Cap stock.


How many employees does UNITY BIOTECHNOLOGY INC have?

UNITY BIOTECHNOLOGY INC (UBX) currently has 19 employees.


What are the support and resistance levels for UNITY BIOTECHNOLOGY INC (UBX) stock?

UNITY BIOTECHNOLOGY INC (UBX) has a support level at 1.01 and a resistance level at 1.13. Check the full technical report for a detailed analysis of UBX support and resistance levels.


Is UNITY BIOTECHNOLOGY INC (UBX) expected to grow?

The Revenue of UNITY BIOTECHNOLOGY INC (UBX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the UBX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy UNITY BIOTECHNOLOGY INC (UBX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does UNITY BIOTECHNOLOGY INC (UBX) stock pay dividends?

UBX does not pay a dividend.


When does UNITY BIOTECHNOLOGY INC (UBX) report earnings?

UNITY BIOTECHNOLOGY INC (UBX) will report earnings on 2025-05-13, after the market close.


What is the Price/Earnings (PE) ratio of UNITY BIOTECHNOLOGY INC (UBX)?

UNITY BIOTECHNOLOGY INC (UBX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.53).


What is the Short Interest ratio of UNITY BIOTECHNOLOGY INC (UBX) stock?

The outstanding short interest for UNITY BIOTECHNOLOGY INC (UBX) is 4.56% of its float. Check the ownership tab for more information on the UBX short interest.


UBX Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to UBX. When comparing the yearly performance of all stocks, UBX is a bad performer in the overall market: 90.08% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

UBX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to UBX. UBX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

UBX Financial Highlights

Over the last trailing twelve months UBX reported a non-GAAP Earnings per Share(EPS) of -1.53. The EPS increased by 40% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -69.01%
ROE -400.22%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-78.57%
Sales Q2Q%N/A
EPS 1Y (TTM)40%
Revenue 1Y (TTM)N/A

UBX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to UBX. The Buy consensus is the average rating of analysts ratings from 8 analysts.

For the next year, analysts expect an EPS growth of 14.98% and a revenue growth -100% for UBX


Ownership
Inst Owners19.61%
Ins Owners0.86%
Short Float %4.56%
Short Ratio4.65
Analysts
Analysts82.5
Price Target5.1 (355.36%)
EPS Next Y14.98%
Revenue Next Year-100%